TAGRISSO is indicated:, as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations, as detected by a validated test., for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have activating EGFR mutations, as detected by a validated test., for the treatment of patients with locally advanced or metastatic NSCLC that is EGFR T790M mutation-positive, as detected by a validated test.
How to take it
The way to take this medicine is: Oral.
This medicine is taken by mouth.
Store below 30 degrees Celsius
Protect from direct sunlight
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Oval, biconvex, beige, film-coated tablets approximately 7.25 x 14.5 mm. The tablets are debossed with AZ 80 on one side and plain on the reverse
Images are the copyright of Medicines Information Pty Ltd
We are currently experiencing issues with Medicines Information data. Images displayed may not be current, please refer to the CMI.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
TAGRISSO is indicated:, as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations, as detected by a validated test., for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have activating EGFR mutations, as detected by a validated test., for the treatment of patients with locally advanced or metastatic NSCLC that is EGFR T790M mutation-positive, as detected by a validated test.
How to take it
The way to take this medicine is: Oral.
This medicine is taken by mouth.
Store below 30 degrees Celsius
Protect from direct sunlight
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
The 40 mg tablets are round, biconvex, beige, film-coated tablets with a diameter of approximately 9 mm. The tablets are debossed with AZ over 40 on one side and plain on the reverse
Images are the copyright of Medicines Information Pty Ltd
We are currently experiencing issues with Medicines Information data. Images displayed may not be current, please refer to the CMI.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.